key: cord-0768907-un1zx59t
authors: Kunal, Shekhar; Gupta, Kashish; Gupta, Sanjay
title: Statins in COVID-19: a new ray of hope
date: 2020-08-11
journal: Heart Lung
DOI: 10.1016/j.hrtlng.2020.07.012
sha: ddb681640f0eaa492ee924921129fd7f1f1b2f09
doc_id: 768907
cord_uid: un1zx59t

nan

Authors have no conflict of interest to disclose Funding information: There was no research funding available for this study

SK and KG contributed to the conception or design of the work. SK, KG, SG contributed to the literature review. SK and KG drafted the manuscript. SG critically revised the manuscript. All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

3

To,

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has spread around the world like a wildfire in the past six months. With a high infectivity rate, the disease has already accounted for nearly ten million cases worldwide with deaths accounting to more than a half a million 1 . A lack of specific drug therapy has prompted a global race to develop or search for newer therapies as well as repurposing the older drugs such as hydroxychloroquine and azithromycin. As better insight has been gained on the disease pathophysiology, focus has now shifted to the use of antivirals (Remdesivir), anti-inflammatory and immunosuppressive agents such as tocilizumab.

Repurposing of old drugs developed for other diseases has an advantage that a detailed information exists regarding the pharmacological and safety profile in humans thus being cost-effective and a time saving strategy 2 . One such class of repurposed drugs which can be of benefit in COVID-19 infection are the statins.

SARS-CoV-2 binds to the angiotensin-converting enzyme-2 (ACE-2) receptors which are present in the type II pneumocytes in lungs, heart and vascular endothelium. Following this, there occurs a down-regulation of ACE-2 receptors, cellular viral replication followed by exocytosis and release of mature virions 3 . SARS-CoV-2 leads to a multisystem inflammatory state due to cytokine storm via activation of Toll-like receptor (TLR) 3, TLR7, TLR8 and TLR9. There occurs a triggering of downstream inflammatory cascade through the TLR-MYD88-NF-κB pathway leading to an increased production of various proinflammatory molecules such as interleukin-1 (IL-1), IL-2, IL-4, IL-6 of which IL-6 is a major cytokine 3 . This causes an increase in vascular permeability, damage to the alveolar epithelial cells and ultimately culminating in acute respiratory distress syndrome. In addition, COVID-19 infection is also associated with coagulopathy and thromboembolic complications including life-threatening pulmonary embolism 3 .

Statins, first discovered in 1976, are potent inhibitors of cholesterol synthesis and have been the mainstay of lipid lowering therapies in patients with cardiovascular diseases 4 .

However, statins also have pleotropic effects which accounts for its anti-inflammatory, antioxidative, immunomodulatory and anti-thrombotic properties 4 4 . Apart from its antiinflammatory properties, statins also affect the vascular endothelial function by increasing production of nitric oxide which is a potent vasodilator and inhibits platelet aggregation thus accounting for its anti-thrombotic properties 5 . In addition, animal models have suggested that statins reduce the expression of plasminogen activator inhibitor-1 and tissue factor thus having a profibrinolytic and anticoagulant activity too 5 (Figure 1 ).

Previous studies have suggested that statin use was associated with improved clinical outcomes in patients with viral or bacterial pneumonia along with a decrease in the systemic inflammatory response. However, most of these studies had included patients with influenza virus or were observational in nature and hence prone to bias 6 . There was a significantly lower crude 28-day mortality in the statin group (mortality rate: 5.5%) as compared to the non-statin group (mortality rate: 6.8%; P = 0.046). In addition, the mixed-effect Cox model after propensity score-matching (for baseline differences between groups) found that the risk for 28-day all-cause mortality was 5.2% in statin group as compared to 9.4% in non-statin groups with an adjusted hazard ratio of 0.58. In addition, the authors also reported that among statin users CRP and IL-6 levels were lower both at admission and prior to discharge with no significant increase during the period of hospitalization. However, a major limitation was the retrospective nature of this study making it difficult to propose a causality assessment between statin use and mortality.

Secondly, despite using propensity matching to match the two groups, multiple unknown confounders may affect the final results. Another retrospective multicenter study to determine the association between ACEi/ARB and/or statin use with outcomes in COVID-19 patients showed a significant association between statin use and absence of symptoms (OR 2.91; CI 1.27-6.71) 9 . However, both the studies were retrospective in nature hence, a need for RCTs regarding the role of statins in COVID-19 patients. The role of statins in reducing thromboembolic complications has been highlighted in a recent study which reported a lower incidence of pulmonary embolism among COVID-19 patients on statin therapy prior to admission 10 . In addition, another beneficial effect of statins in COVID-19 infection could be its cardioprotective action. Since patients with COVID-19 has been predisposed to myocardial injury which portrays a bad prognostic, use of statins could be protective in these patients 3 .

One of the major side-effects of statin use is drug-induced myotoxicity which ranges from mild symptoms of myalgias to myopathies and rhabdomyolysis leading to acute kidney injury. In addition, statins are also known to cause hepatotoxicity and increase in liver enzymes. Critically ill patients with advanced liver and renal involvement are often predisposed to these side-effects of statins. Initiating statins in critically ill COVID-19 patients can lead to an increased risk of myopathy as well as associated renal damage hence, a poor prognosis 4 . 

An interactive web-based dashboard to track COVID-19 in real time

Drug repurposing in the era of COVID-19: a call for leadership and government investment

Cardiovascular system and COVID-19: perspectives from a developing country

Statins as potent antiinflammatory drugs

Statins as antithrombotic drugs

Treating influenza with statins and other immunomodulatory agents

Cholesterol-lowering treatment may worsen the outcome of a Covid-19 infection

In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents

Acute Pulmonary Embolism and COVID-19